These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 27231940

  • 1. Effects of OnabotulintoxinA on Habituation of Laser Evoked Responses in Chronic Migraine.
    de Tommaso M, Delussi M, Ricci K, Montemurno A, Carbone I, Vecchio E.
    Toxins (Basel); 2016 May 25; 8(6):. PubMed ID: 27231940
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Lack of habituation of nociceptive evoked responses and pain sensitivity during migraine attack.
    de Tommaso M, Lo Sito L, Di Fruscolo O, Sardaro M, Pia Prudenzano M, Lamberti P, Livrea P.
    Clin Neurophysiol; 2005 Jun 25; 116(6):1254-64. PubMed ID: 15978487
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Habituation of laser-evoked potentials by migraine phase: a blinded longitudinal study.
    Uglem M, Omland PM, Stjern M, Gravdahl GB, Sand T.
    J Headache Pain; 2017 Oct 02; 18(1):100. PubMed ID: 28971336
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R, Schreiber C.
    Headache; 2008 Jun 02; 48(6):900-13. PubMed ID: 18047501
    [Abstract] [Full Text] [Related]

  • 11. Update on laser-evoked potential findings in fibromyalgia patients in light of clinical and skin biopsy features.
    de Tommaso M, Nolano M, Iannone F, Vecchio E, Ricci K, Lorenzo M, Delussi M, Girolamo F, Lavolpe V, Provitera V, Stancanelli A, Lapadula G, Livrea P.
    J Neurol; 2014 Mar 02; 261(3):461-72. PubMed ID: 24366650
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A Retrospective Real-Life Multicenter Study on Concurrent Oral Preventive Treatments in Patients with Chronic Migraine Treated with OnabotulinumtoxinA.
    Overeem LH, Ornello R, Pocora MM, Reuter U, Sacco S, Tassorelli C, Dueland AN, Raffaelli B, Martinelli D.
    CNS Drugs; 2023 May 02; 37(5):453-465. PubMed ID: 37212943
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
    Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT Chronic Migraine Study Group.
    Headache; 2010 Jun 02; 50(6):921-36. PubMed ID: 20487038
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.